Dextropropoxyphene is excreted in breast milk. Drowsiness and difficulty in feeding could

occur in these infants, especially if the mother is on long term therapy. Long term prescribing

should therefore be avoided.

A close relative of methadone, dextropropoxyphene was first marketed in 1957 under the trade name of Darvon®. Oral analgesic potency is one-half to one-third that of codeine, with 65 mg approximately equivalent to about 600 mg of aspirin. Dextropropoxyphene is prescribed for relief of mild to moderate pain. Bulk dextropropoxyphene is in Schedule II, while preparations containing it are in Schedule IV. More than 100 tons of dextropropoxyphene are produced in the United States annually, and more than 30 million prescriptions are written for the products. This narcotic is associated with a number of toxic side effects and is among the top 10 drugs reported by medical examiners in drug abuse deaths.

Also known as Dextropropoxyphene, propoxyphene napsylate is an analgesic used to treat mild pain, and is an anti-tussive and local anesthetic.

Also known as Dextropropoxyphene, propoxyphene napsylate is an analgesic used to treat mild pain, and is an anti-tussive and local anesthetic.

It is a prescription drug in tablet form, used for severe pain.

Each tablet contains 32.5mg Dextropropoxyphene Hydrochloride and 325g Paracetamol.